GoKawiilDespite recent advancements in oncology, the branch of medicine focused on the study, prevention, diagnosis and treatment of cancer, it remains one of the most expensive, arduous and overwhelming diagnoses to navigate. Thyme Care, launched in 2020 and ranked No. 18 on the 2026 CNBC Disruptor 50 list, has focused on improving the fragmentation and disconnections in cancer care through its virtual navigation platform for patients.
To extend its efforts, Thyme Care has raised $125 million from investors in a Series E funding round at a valuation of more than $2 billion, it announced on Wednesday. The deal, led by Morgan Health with participation from strategic healthcare investors Humana and CVS Health Ventures, roughly doubled its valuation from a Series D less than a year ago. Other investors include AlleyCorp, HealthQuest Capital, and a16z Bio + Health.
Thyme Care is now forming a new parent company focused on building additional businesses that will address some of those disconnections in how cancer care is delivered, accessed and paid for.
Robin Shah, who co-founded Thyme Care alongside Bobby Green, will serve as the executive chairman of the new parent entity, which will be called Thyme Companies. Shah said that the timing was right to take this next step in the journey to improve the cancer care system.
"When Bobby and I started this business six years ago, we had this vision that we needed to go after all the white spaces that were being constantly overlooked in oncology," said Shah, adding that Thyme Care aimed to address "the care in between," or the things and questions that come up between appointments and visits.
Thyme Care has grow into that role. The company's services are available to more than 10.5 million people across all 50 U.S. states, and it manages more than $7 billion in oncology spend. Revenue surpassed $125 million last year, five times more than the previous year.